MX2021011438A - Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. - Google Patents
Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.Info
- Publication number
- MX2021011438A MX2021011438A MX2021011438A MX2021011438A MX2021011438A MX 2021011438 A MX2021011438 A MX 2021011438A MX 2021011438 A MX2021011438 A MX 2021011438A MX 2021011438 A MX2021011438 A MX 2021011438A MX 2021011438 A MX2021011438 A MX 2021011438A
- Authority
- MX
- Mexico
- Prior art keywords
- imidazopyrrolopyridine
- kinases
- inhibitors
- jak family
- methods
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos de 2-((1r,4r)-4-(imidazo[4,5-d]pirrolo[2,3-b]piridin-1( 6H)-il)ciclohexil)acetonitrilo, composiciones farmacéuticas que los contienen, métodos para elaborarlos, y métodos para usarlos que incluyen métodos para tratar enfermedades, desórdenes y condiciones mediadas por JAK, tales como la enfermedad inflamatoria del intestino.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435639P | 2016-12-16 | 2016-12-16 | |
US201762592747P | 2017-11-30 | 2017-11-30 | |
US201762596636P | 2017-12-08 | 2017-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011438A true MX2021011438A (es) | 2021-10-13 |
Family
ID=60937954
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007084A MX2019007084A (es) | 2016-12-16 | 2017-12-15 | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. |
MX2021011438A MX2021011438A (es) | 2016-12-16 | 2019-06-14 | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007084A MX2019007084A (es) | 2016-12-16 | 2017-12-15 | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. |
Country Status (21)
Country | Link |
---|---|
US (2) | US10981911B2 (es) |
EP (1) | EP3555096B1 (es) |
JP (2) | JP7153647B2 (es) |
KR (1) | KR102565224B1 (es) |
CN (2) | CN114685505A (es) |
AU (2) | AU2017377072B2 (es) |
BR (1) | BR112019012264A2 (es) |
CA (1) | CA3047311A1 (es) |
CL (1) | CL2019001633A1 (es) |
CO (1) | CO2019006858A2 (es) |
EC (1) | ECSP19047936A (es) |
ES (1) | ES2935392T3 (es) |
IL (2) | IL267215B (es) |
JO (1) | JOP20190144A1 (es) |
MX (2) | MX2019007084A (es) |
MY (1) | MY196805A (es) |
NI (1) | NI201900061A (es) |
PE (1) | PE20191499A1 (es) |
PH (1) | PH12019501355A1 (es) |
UA (1) | UA123689C2 (es) |
WO (1) | WO2018112382A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3640251T (lt) | 2016-10-24 | 2022-03-10 | Astrazeneca Ab | 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui |
EP4086256A1 (en) | 2016-12-16 | 2022-11-09 | Janssen Pharmaceutica NV | Small molecule inhibitors of the jak family of kinases |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
JOP20190144A1 (ar) * | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
EP3568396B1 (en) | 2017-01-11 | 2020-11-11 | Leo Pharma A/S | Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
BR112019015389A2 (pt) | 2017-01-30 | 2020-03-10 | Astrazeneca Ab | Moduladores de receptores de estrogênio |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
CN114128028A (zh) | 2019-07-30 | 2022-03-01 | 株式会社Lg化学 | 用于电化学装置的复合隔板和包括该复合隔板的电化学装置 |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
EP4175719A1 (en) * | 2020-07-02 | 2023-05-10 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
CN113292561A (zh) * | 2021-05-22 | 2021-08-24 | 中国药科大学 | 一种二吡咯并吡啶结构的化合物、制备方法和医药用途 |
WO2023194840A1 (en) * | 2022-04-05 | 2023-10-12 | Unichem Laboratories Limited | Substituted tricyclic compounds and their use in covid-19 |
WO2023194842A1 (en) * | 2022-04-05 | 2023-10-12 | Unichem Laboratories Limited | Substituted tricyclic compounds and their use in rheumatoid arthritis |
WO2023194841A1 (en) * | 2022-04-05 | 2023-10-12 | Unichem Laboratories Limited | Substituted tricyclic compounds and their use in ulcerative colitis |
WO2023248010A2 (en) | 2022-06-23 | 2023-12-28 | Synovo Gmbh | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
AU765005B2 (en) | 1999-04-23 | 2003-09-04 | Smithkline Beecham Plc | Polymorph of 5-(4-(2- (N-methyl-N-( 2-pyridyl)amino) ethoxy)benzyl) thiazolidine-2,4-dione, maleic acid salt |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
ES2299720T3 (es) | 2002-05-31 | 2008-06-01 | Schering Corporation | Formas polimorfas de un inhibidor de xantina-fosfodiesterasa v. |
GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
CA2613053C (en) | 2005-07-01 | 2015-11-24 | Wyeth | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
AU2012201894A1 (en) * | 2005-12-13 | 2012-04-19 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
JP5432982B2 (ja) * | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | アポトーシスシグナル調節キナーゼ1阻害剤 |
WO2009152133A1 (en) | 2008-06-10 | 2009-12-17 | Abbott Laboratories | Novel tricyclic compounds |
ES2505270T3 (es) | 2009-09-03 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibidores de JAK2 y su uso para el tratamiento de enfermedades mieloproliferativas y cáncer |
SI2506716T1 (sl) | 2009-12-01 | 2017-10-30 | Abb Vie Inc. | Nove triciklične spojine |
US8785639B2 (en) | 2009-12-01 | 2014-07-22 | Abbvie Inc. | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof |
CA2781578A1 (en) * | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
EP2534258B1 (en) | 2010-02-10 | 2017-09-20 | Genon Biotechnologies OY | Dual activity kinase domains and uses thereof |
WO2013007765A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
US9475813B2 (en) | 2013-02-08 | 2016-10-25 | Nissan Chemical Industries, Ltd. | Tricyclic pyrrolopyridine compound, and JAK inhibitor |
EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
SG11201608542YA (en) | 2014-05-14 | 2016-11-29 | Nissan Chemical Ind Ltd | Tricyclic compound and jak inhibitor |
HUE046130T2 (hu) | 2015-05-28 | 2020-02-28 | Theravance Biopharma R&D Ip Llc | Naftiridin vegyületek mint jak kináz inhibitorok |
WO2017079639A1 (en) | 2015-11-04 | 2017-05-11 | Mayo Foundation For Medical Education And Research | Methods and materials for treating autoimmune conditions |
JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
LT3640251T (lt) | 2016-10-24 | 2022-03-10 | Astrazeneca Ab | 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui |
MX2019007120A (es) | 2016-12-16 | 2019-09-16 | Basf Se | Compuestos plaguicidas. |
CU24573B1 (es) | 2016-12-16 | 2022-01-13 | Pfizer | Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas |
UA123640C2 (uk) | 2016-12-16 | 2021-05-05 | Елі Ліллі Енд Компані | Сполука 7-фенілетиламіно-4н-піримідо[4,5-d][1,3]оксазин-2-ону (варіанти) як інгібітор мутантів idh1 та idh2 |
US20190281874A1 (en) | 2016-12-16 | 2019-09-19 | Nestec S.A. | Oligosaccharides for flavour generation |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
EP4086256A1 (en) | 2016-12-16 | 2022-11-09 | Janssen Pharmaceutica NV | Small molecule inhibitors of the jak family of kinases |
EP3568396B1 (en) | 2017-01-11 | 2020-11-11 | Leo Pharma A/S | Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
BR112019015389A2 (pt) | 2017-01-30 | 2020-03-10 | Astrazeneca Ab | Moduladores de receptores de estrogênio |
CA3059939A1 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
WO2020216936A1 (en) * | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
AU2022233254A1 (en) * | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
-
2017
- 2017-06-16 JO JOP/2019/0144A patent/JOP20190144A1/ar unknown
- 2017-12-15 PE PE2019001273A patent/PE20191499A1/es unknown
- 2017-12-15 CN CN202210363548.7A patent/CN114685505A/zh active Pending
- 2017-12-15 CA CA3047311A patent/CA3047311A1/en active Pending
- 2017-12-15 BR BR112019012264A patent/BR112019012264A2/pt active Search and Examination
- 2017-12-15 IL IL267215A patent/IL267215B/en unknown
- 2017-12-15 MY MYPI2019003415A patent/MY196805A/en unknown
- 2017-12-15 UA UAA201908084A patent/UA123689C2/uk unknown
- 2017-12-15 KR KR1020197020735A patent/KR102565224B1/ko active IP Right Grant
- 2017-12-15 JP JP2019531906A patent/JP7153647B2/ja active Active
- 2017-12-15 MX MX2019007084A patent/MX2019007084A/es unknown
- 2017-12-15 IL IL295461A patent/IL295461A/en unknown
- 2017-12-15 US US16/469,939 patent/US10981911B2/en active Active
- 2017-12-15 AU AU2017377072A patent/AU2017377072B2/en active Active
- 2017-12-15 WO PCT/US2017/066754 patent/WO2018112382A1/en unknown
- 2017-12-15 EP EP17826097.2A patent/EP3555096B1/en active Active
- 2017-12-15 CN CN201780086744.1A patent/CN110312719B/zh active Active
- 2017-12-15 ES ES17826097T patent/ES2935392T3/es active Active
-
2019
- 2019-06-13 CL CL2019001633A patent/CL2019001633A1/es unknown
- 2019-06-14 PH PH12019501355A patent/PH12019501355A1/en unknown
- 2019-06-14 MX MX2021011438A patent/MX2021011438A/es unknown
- 2019-06-14 NI NI201900061A patent/NI201900061A/es unknown
- 2019-06-26 CO CONC2019/0006858A patent/CO2019006858A2/es unknown
- 2019-07-05 EC ECSENADI201947936A patent/ECSP19047936A/es unknown
-
2021
- 2021-03-16 US US17/202,887 patent/US11827638B2/en active Active
- 2021-11-24 AU AU2021273566A patent/AU2021273566B2/en active Active
-
2022
- 2022-04-26 JP JP2022072068A patent/JP7441264B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021011438A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak. | |
PH12019501254A1 (en) | Small molecule inhibitors of the jak family of kinases | |
MX2020013688A (es) | Inhibidores de moleculas peque?as de la familia de quinasas jak. | |
EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
EA201891067A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ | |
MY169268A (en) | Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases | |
MX2018004517A (es) | Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). | |
NZ714742A (en) | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use | |
IL267801B1 (en) | Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds | |
EA201991473A1 (ru) | Имидазопирролопиридин в качестве ингибиторов киназ семейства jak | |
EA201991472A1 (ru) | Низкомолекулярные ингибиторы киназ семейства jak | |
EA202190047A1 (ru) | Низкомолекулярные ингибиторы киназ семейства jak | |
CR20190283A (es) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases | |
AR114969A1 (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak |